1. Selection methods for high-producing mammalian cell lines
2. International Conference on Harmonization.ICH Harmonised Tripartite Guideline: Derivation and Characterization of Cell Substrates used for Production of Biotechnological/Biological Products Q5D. International Conference on Harmonization; 1997. Published Federal Register. 1998; 63.182:50244-50249. Available at:http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5D/Step4/Q5D_Guideline.pdf. Accessed May 15 2014.
3. Center for Biologics Evaluation and Research (CBER) U.S.Supplement to the Points to Consider in the Production and Testing of New Drugs and Biologic Produced by Recombinant DNA Technology: Nucleic Acid Characterization and Genetic Stability. U.S. Food and Drug Administration; 1992. Available at:http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatory information/otherrecommendationsformanufacturers/ucm062777.pdf. Accessed May 15 2014.
4. World Health Organization.Guidelines on the Quality Safety and Efficacy of Biotherapeutic Protein Products Prepared by Recombinant DNA Technology. Annex 3 in WHO Expert Committee on Biological Standardization.Sixty‐First Report. WHO Technical Report Series No. 978. WHO Press World Health Organization; 2013. Available at:http://www.who.int/biologicals/expert_committee/TRS_978_61st_report.pdf. Accessed May 15 2014.